Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Johnson

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
JACC. Clinical Electrophysiology|August 25, 2018
Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk EstimatesWayne C Levy, Anne S Hellkamp, Daniel B Mark, et al.
Heart Rhythm|October 2, 2010
An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure TrialDavid G Strauss, Jeanne E Poole, Galen S Wagner, et al.
BMC Public Health|September 11, 2023
Factors impacting resident outcomes from COVID-19 outbreaks in Residential Aged Care Facilities in Sydney Local Health District: testing an infection prevention and control scoring systemAlison Stubbs, Elizabeth Dawson, Elise Campbell, et al.
Resuscitation|September 9, 2021
Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT)Monique Anderson Starks, Larry R Jackson, Anne Hellkamp, et al.
Environmental and Molecular Mutagenesis|December 20, 2023
Interpretation of in vitro concentration-response data for risk assessment and regulatory decision-making: Report from the 2022 IWGT quantitative analysis expert working group meetingMarc A Beal, Guangchao Chen, Kerry L Dearfield, et al.
Circulation|July 5, 2006
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Daniel B Mark, Charlotte L Nelson, Kevin J Anstrom, et al.
Circulation|August 26, 2009
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure populationWayne C Levy, Kerry L Lee, Anne S Hellkamp, et al.
Journal of the American College of Cardiology|July 25, 2020
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFTJeanne E Poole, Brian Olshansky, Daniel B Mark, et al.
European Journal of Medicinal Chemistry|September 18, 2021
Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisationGilda Padalino, Nelly El-Sakkary, Lawrence J Liu, et al.
Environmental and Molecular Mutagenesis|December 10, 2022
Quantitative in vitro to in vivo extrapolation of genotoxicity data provides protective estimates of in vivo doseMarc A Beal, Marc Audebert, Tara Barton-Maclaren, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
JACC. Clinical Electrophysiology|August 25, 2018
Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk EstimatesWayne C Levy, Anne S Hellkamp, Daniel B Mark, et al.
Heart Rhythm|October 2, 2010
An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure TrialDavid G Strauss, Jeanne E Poole, Galen S Wagner, et al.
BMC Public Health|September 11, 2023
Factors impacting resident outcomes from COVID-19 outbreaks in Residential Aged Care Facilities in Sydney Local Health District: testing an infection prevention and control scoring systemAlison Stubbs, Elizabeth Dawson, Elise Campbell, et al.
Resuscitation|September 9, 2021
Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT)Monique Anderson Starks, Larry R Jackson, Anne Hellkamp, et al.
Environmental and Molecular Mutagenesis|December 20, 2023
Interpretation of in vitro concentration-response data for risk assessment and regulatory decision-making: Report from the 2022 IWGT quantitative analysis expert working group meetingMarc A Beal, Guangchao Chen, Kerry L Dearfield, et al.
Circulation|July 5, 2006
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Daniel B Mark, Charlotte L Nelson, Kevin J Anstrom, et al.
Circulation|August 26, 2009
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure populationWayne C Levy, Kerry L Lee, Anne S Hellkamp, et al.
Journal of the American College of Cardiology|July 25, 2020
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFTJeanne E Poole, Brian Olshansky, Daniel B Mark, et al.
European Journal of Medicinal Chemistry|September 18, 2021
Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisationGilda Padalino, Nelly El-Sakkary, Lawrence J Liu, et al.
Environmental and Molecular Mutagenesis|December 10, 2022
Quantitative in vitro to in vivo extrapolation of genotoxicity data provides protective estimates of in vivo doseMarc A Beal, Marc Audebert, Tara Barton-Maclaren, et al.
Pageof 10